已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.

医学 佐剂 免疫疗法 癌症 化疗 肿瘤科 内科学 辅助化疗 乳腺癌
作者
Florian Lordick,M. Mauer,Gertraud Stocker,C.A. Cella,Irit Ben‐Aharon,Guillaume Piessen,L. Wyrwicz,Ghazwan Al-Haidari,Tania Fleitas,Valérie Boige,Radka Obermannová,Ute Martens,Carlos Gómez-Martín,Peter Thuss‐Patience,Virginia Arrazubi,Antonio Avallone,Kai‐Keen Shiu,P Artru,Baruch Brenner,C. Bugés Sánchez
出处
期刊:Annals of Oncology [Elsevier BV]
被引量:3
标识
DOI:10.1016/j.annonc.2024.10.829
摘要

Patients with gastro-oesophageal adenocarcinoma with tumour-positive lymph nodes (ypN+) or positive surgical margins (R1) following neoadjuvant chemotherapy and resection are at high risk of recurrence. Adjuvant nivolumab is effective in oesophageal/oesophagogastric junction cancer and residual pathological disease following chemoradiation and surgery. Immune checkpoint inhibition has shown efficacy in advanced gastro-oesophageal cancer. We hypothesised that nivolumab/ipilimumab would be more effective than adjuvant chemotherapy in high-risk (ypN+ and/or R1) patients with gastro-oesophageal adenocarcinoma following neoadjuvant chemotherapy and resection. VESTIGE was an academic international, multicentre, open-label, randomised phase II trial evaluating the efficacy of adjuvant nivolumab/ipilimumab versus chemotherapy in gastro-oesophageal adenocarcinoma at high risk of recurrence. Patients were randomised 1 : 1 to receive standard adjuvant chemotherapy (same regimen as neoadjuvant) or nivolumab 3 mg/kg intravenously (i.v.) every 2 weeks plus ipilimumab 1 mg/kg i.v. every 6 weeks for 1 year. Key inclusion criteria included ypN+ and/or R1 status after neoadjuvant chemotherapy plus surgery. The primary endpoint was disease-free survival in the intent-to-treat population. Secondary endpoints included overall survival, locoregional and distant failure rates, and safety according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. The independent Data Monitoring Committee reviewed data from 189 of the planned 240 patients in June 2022 and recommended stopping recruitment due to futility. At the time of final analysis, median follow-up was 25.3 months for 195 patients (98 nivolumab/ipilimumab and 97 chemotherapy). Median disease-free survival for the nivolumab/ipilimumab group was 11.4 months [95% confidence interval (CI) 8.4-16.8 months] versus 20.8 months (95% CI 15.0-29.9 months) for the chemotherapy group, hazard ratio 1.55 (95% CI 1.07-2.25, one-sided P = 0.99). The 12-month disease-free survival rates were 47.1% and 64.0%, respectively. There were no toxicity concerns or excess early discontinuations. Nivolumab/ipilimumab did not improve disease-free survival compared with chemotherapy in patients with ypN+ and/or R1 gastro-oesophageal adenocarcinoma following neoadjuvant chemotherapy and surgery.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
伶俐的高烽完成签到 ,获得积分10
2秒前
慕子默完成签到,获得积分10
3秒前
10秒前
zzy完成签到 ,获得积分10
11秒前
12秒前
12秒前
辛夷发布了新的文献求助10
15秒前
only完成签到 ,获得积分10
15秒前
江姜酱先生完成签到,获得积分10
15秒前
Jasonjoey发布了新的文献求助10
15秒前
小真白发布了新的文献求助10
15秒前
充电宝应助科研通管家采纳,获得10
16秒前
SciGPT应助科研通管家采纳,获得10
16秒前
搜集达人应助科研通管家采纳,获得10
16秒前
aldehyde应助科研通管家采纳,获得10
16秒前
16秒前
大模型应助科研通管家采纳,获得10
16秒前
科研通AI5应助科研通管家采纳,获得50
16秒前
16秒前
Owen应助科研通管家采纳,获得10
16秒前
清欢完成签到,获得积分10
20秒前
Li发布了新的文献求助10
21秒前
Jasonjoey完成签到,获得积分10
23秒前
24秒前
天天快乐应助Li采纳,获得10
27秒前
大个应助悠悠我心采纳,获得30
28秒前
小冠军完成签到,获得积分10
28秒前
30秒前
害羞便当完成签到 ,获得积分10
30秒前
情怀应助小刘采纳,获得10
31秒前
zhouleiwang发布了新的文献求助10
31秒前
斯文败类应助bing采纳,获得10
33秒前
大胆灵竹发布了新的文献求助10
36秒前
39秒前
希望天下0贩的0应助sigrid采纳,获得10
42秒前
完美世界应助淡定的半梦采纳,获得10
45秒前
ding应助很好采纳,获得10
45秒前
bing发布了新的文献求助10
46秒前
48秒前
弧光完成签到 ,获得积分0
48秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989989
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256053
捐赠科研通 3270900
什么是DOI,文献DOI怎么找? 1805105
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216